The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [Midatech Pharma plc]

27 May 2020 07:00

RNS Number : 9950N
Lind Partners, LLC (The)
26 May 2020
 

FORM 8.3

 

PUBLIC DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

The Lind Partners, LLC

 

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

22 May 2020, in addition, The Lind Partners has dealt further in previous days during the offer period as shown in the bottom of the form.

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

N/A

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

US ADRs: US59564R3021

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

80,040 ADRs

(equivalent to 400,200 shares)

1.02

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

80,040 ADRs

(equivalent to 400,200 shares)

1.02

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Warrants to purchase ADRs

Details, including nature of the rights concerned and relevant percentages:

193,940 warrants with a strike price of USD 2.05 issued without payment alongside placement of an equivalent number of ADRs on 18 May 2020

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

US ADRs (US59564R3021)

Sale

 

15,000

USD 1.437

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES/NO NO

 

 

Date of disclosure:

26 May 2020

Contact name:

Samantha Chun

Telephone number*:

+1(646) 701-7424

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

Class of relevant security

Date

Purchase/sale

 

Number of securities

Price per unit

US ADRs (US59564R3021)

18 May 2020

Subscription (issuance of ADRs pursuant to a private placement)

 

193,940

 

USD 1.65

 

US ADRs (US59564R3021)

18 May 2020

Sale

51,400

USD 1.614

US ADRs (US59564R3021)

19 May 2020

Sale

17,500

USD 1.578

US ADRs (US59564R3021)

20 May 2020

Sale

15,000

USD 1.509

US ADRs (US59564R3021)

21 May 2020

Sale

15,000

USD 1.485

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETKKABNOBKDDPB
Date   Source Headline
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 201910:52 amRNSHolding(s) in Company
26th Feb 201911:26 amRNSFinalisation of Licence Agreement
25th Feb 201912:23 pmRNSResult of the General Meeting and Board changes
8th Feb 20194:39 pmRNSPosting of Circular and Notice of General Meeting
4th Feb 20196:32 pmRNSResult of Placing
4th Feb 20193:16 pmRNSProposed Placing and Open Offer
29th Jan 20199:23 amRNSStrategic Investment & Licence Agreement
25th Jan 20197:00 amRNSFDA feedback on clinical plan for MTD201
15th Jan 20191:56 pmRNSHolding(s) in Company
15th Jan 20199:36 amRNSHolding(s) in Company
11th Jan 201910:58 amRNSHolding(s) in Company
10th Jan 201911:15 amRNSMidatech announces EUR 1.5 million loan facility
20th Dec 20187:00 amRNSCorporate update and potential fundraise
20th Dec 20187:00 amRNSMidatech Announces Microsphere Partnership
28th Nov 20181:17 pmRNSHolding(s) in Company
20th Nov 201812:59 pmRNSHolding(s) in Company
5th Nov 20189:55 amRNSHolding(s) in Company
1st Nov 20185:48 pmRNSNASDAQ Minimum Bid Price Extension
1st Nov 20187:00 amRNSCompletion of Midatech Pharma US Sale
15th Oct 201812:17 pmRNSResult of General Meeting
28th Sep 201810:04 amRNSPosting of Circular and Notice of General Meeting
27th Sep 20187:01 amRNSInterim Results
27th Sep 20187:00 amRNSProposed Sale of Midatech Pharma US Inc
6th Sep 20187:00 amRNSNotice of Interim Results
31st Aug 20187:00 amRNSInterim results from MTD201 exploratory study
1st Aug 20187:00 amRNSIssue of Equity for Midatech Share Incentive Plan
25th Jul 20187:00 amRNSTrading Update
23rd Jul 20187:00 amRNSUS Co-Promotion Agreement
27th Jun 201810:56 amRNSResult of AGM
8th Jun 20187:00 amRNSMidatech US enrols patient in Gelclair trial
1st Jun 20187:00 amRNSBoard change
1st Jun 20187:00 amRNS2017 Annual Report and AGM Notification
25th May 20187:00 amRNSMidatech commences US clinical study with MTX110
21st May 20187:00 amRNSMidatech commences dosing in equivalence study
8th May 20187:00 amRNSSEC filing regarding share price movement
3rd May 201812:15 pmRNSMidatech Announces Receipt of NASDAQ Notice
3rd May 20187:00 amRNSStmnt re Share Price Movement
2nd May 20184:40 pmRNSSecond Price Monitoring Extn
2nd May 20184:35 pmRNSPrice Monitoring Extension
23rd Apr 20187:00 amRNSFinancial results for year ended 31 December 2017
9th Apr 20188:25 amRNSNotice of Results
15th Mar 20187:00 amRNSChanges in Senior Management Team
28th Feb 20187:00 amRNSMidatech gets Orphan Drug Designation for MTD119
14th Feb 20187:00 amRNSTrading Update
16th Jan 20187:00 amRNSIND approval for DIPG treatment MTX110
9th Jan 20187:00 amRNSQ-Octreotide first in-human EU study approved
3rd Jan 20181:36 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSMidatech Loan Agreement with MidCap Financial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.